Loading organizations...
§ Private Profile · Palo Alto, CA, USA
AI-driven business operating system for mission-critical enterprises.
RISA Labs develops an AI operating system designed to automate critical workflows within oncology. Their primary offering, the BOSS Console, streamlines processes such as prior authorizations, aiming to reduce treatment delays, minimize administrative burdens, and accelerate the overall delivery of patient care. The company leverages artificial intelligence to bring efficiency and precision to complex operational challenges specific to cancer treatment centers.
The company was co-founded by Kshitij Jaggi and Kumar Shivang. Their insight stemmed from the significant operational inefficiencies and delays prevalent in oncology, particularly around administrative tasks like securing treatment approvals. They identified a clear need for an intelligent system that could alleviate these bottlenecks, allowing healthcare providers to focus more on patient outcomes rather than administrative hurdles.
RISA Labs serves leading healthcare institutions and oncology practices, providing tools that enhance operational effectiveness. Their vision is to scale this AI-driven approach nationwide, ensuring that more patients can access timely and efficient cancer care by eliminating common authorization delays and denials. The company works towards a future where technology empowers oncology centers to deliver superior care seamlessly.
RISA Labs has raised $15.1M across 2 funding rounds.
RISA Labs has raised $15.1M in total across 2 funding rounds.
RISA Labs is an early-stage healthcare technology company founded in 2024 that builds an AI-powered platform automating prior authorizations for oncology treatments.[1][2] Its core product, BOSS, serves hospitals and healthcare providers by slashing prior authorization time from 30 minutes to under five minutes through AI agents that handle medical necessity checks, form population, submission via APIs/portals/e-fax, and denial management.[1][2] The platform tackles administrative burdens in oncology workflows, reducing denial rates, compliance risks, and manual labor while integrating with 90+ EHRs like Epic and Cerner, positioning it for growth in the $80 billion global healthcare automation market after raising $3.5M in seed funding from Z47 and 3States.[1][3]
RISA Labs was founded in 2024 in Palo Alto, California, by Kshitij Jaggi and Kumar Shivang as a three-person "AI Research group" focused on multi-agent systems for healthcare operations.[1][4] The idea emerged from the healthcare community's need to reimagine oncology workflows, starting with prior authorizations—a notorious bottleneck involving payer rules, EHR data, and manual tasks.[2][4] Early traction came swiftly with a seed VC round of $3.5M just two months before mid-2025, validating their AI-driven approach amid rising demand for automation in high-risk care.[1]
RISA Labs rides the AI healthcare automation wave, targeting oncology's administrative inefficiencies amid payer scrutiny and rising treatment costs.[1][2] Timing aligns with post-2024 AI maturity in multi-agent systems and regulatory pushes for faster approvals, fueled by a $80B market opportunity as providers face burnout from 30-minute auths.[1] It influences the ecosystem by enabling unified AI orchestration across oncology nodes, integrating with incumbents like Availity, and reducing denials—potentially scaling to general healthcare ops and pressuring legacy players to adopt AI.[2][3]
RISA Labs is primed to expand BOSS beyond prior auth into full oncology orchestration, leveraging its seed momentum and integrations to capture market share in a denial-plagued sector.[1][2] Trends like AI agent proliferation, FHIR standardization, and value-based care will accelerate adoption, though competition from AKASA and scaling human-AI handoffs pose risks. Its influence could evolve from niche oncology disruptor to foundational layer in precision healthcare ops, amplifying provider efficiency and patient access in an AI-redefined industry.[1][5]
RISA Labs has raised $15.1M across 2 funding rounds. Most recently, it raised $11.1M Series A in January 2026.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 13, 2026 | $11.1M Series A | Jason Dinger, Optum Ventures | Binny Bansal, Oncology Ventures, Z21 Ventures | Announced |
| Apr 1, 2025 | $4M Seed | Binny Bansal | Alpha Venture Partners, Santé Ventures, Ashish Gupta, General Catalyst, ODD Bird VC, BEN Freeberg, Z21 Ventures | Announced |
RISA Labs has raised $15.1M in total across 2 funding rounds.
RISA Labs's investors include Jason Dinger, Optum Ventures, Binny Bansal, Oncology Ventures, Z21 Ventures, Alpha Venture Partners, Santé Ventures, Ashish Gupta, General Catalyst, ODD BIRD VC, Ben Freeberg.